Placebo + Standardized diet and physical activity counseling throughout the study. + Retatrutide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Feb 2026: Trial started, NCT07467447
  2. 12 Mar 2026: Trial registered, NCT07467447

The trials

NCT07467447: Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight

State
Under way
Phase
Phase 2
People
300 planned
Started
15 Feb 2026
Primary completion
14 Mar 2027
Arms
Retatrutide (LY3437943) 1 mg once weekly (no escalation), Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg., Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation)., Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg, Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg., Placebo once weekly (matched escalation schedule to maintain blinding)., Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.
Results
None posted
  1. 15 Feb 2026: Trial started
  2. 12 Mar 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.